Skip to main content
Indoco Remedies Ltd. logo

Indoco Remedies Ltd. — Investor Relations & Filings

Ticker · INDOCO ISIN · INE873D01024 LEI · 3358007XE9RRPHJA6U47 BSE.NS Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2021-02-09 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS INDOCO

About Indoco Remedies Ltd.

https://www.indoco.com/

Indoco Remedies Ltd. is a fully integrated pharmaceutical company engaged in the research, development, manufacturing, and marketing of finished dosages and Active Pharmaceutical Ingredients (APIs). The company operates multiple manufacturing facilities equipped to produce various dosage forms, including tablets, capsules, injectables, ophthalmics, and topical preparations. Its therapeutic portfolio spans stomatologicals, anti-infectives, respiratory, cardiovascular, anti-diabetics, and pain management. Indoco maintains a significant global footprint, exporting products to over 55 countries, including highly regulated markets such as the United States and Europe. The organization is recognized for its strong research and development capabilities, focusing on complex generics and niche formulations. Key brands include Sensodent-K, Febrex Plus, and Cyclopam, reflecting its leadership in specific therapeutic segments.

Recent filings

Filing Released Lang Actions
Financial Results Updates
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial disclosure from Indoco Remedies Limited dated February 9, 2021. It includes standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2020. The document contains comprehensive financial data such as income from operations, expenses, profit before tax, tax expenses, earnings per share, segment information, and notes. It also includes an Independent Auditors' Limited Review Report pursuant to SEBI regulations, indicating it is an interim financial report. The presence of quarterly and nine-month financial data, unaudited results, and the limited review report aligns with the characteristics of an Interim / Quarterly Report (IR). The document is not merely an announcement or a certification but contains substantive financial data and analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is Interim / Quarterly Report (IR). 9M 2021
2021-02-09 English
Financial Result Updates
Regulatory Filings
2021-02-09 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 60% confidence The document is an invitation to a conference call to discuss the 3QFY21 results of Indoco Remedies Limited. It includes details about the date, time, and participants of the call, as well as dial-in numbers. There are no actual financial statements or substantive financial data presented in the text. The document is short (2401 characters) and serves as an announcement or invitation rather than the transcript or report itself. Therefore, it fits best as a Call Transcript (CT) invitation or announcement. However, since it is only an invitation and not the transcript itself, it does not qualify as a full Call Transcript. Given the options, the closest classification is Call Transcript (CT) because it relates directly to a conference call about earnings results, but it is not the transcript itself. Confidence is moderate due to the nature of the document being an invitation rather than the transcript.
2021-01-22 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the publication of a notice for a Board Meeting. It mentions the notice was published in newspapers and is a communication about the scheduling of a board meeting. There is no financial data, no report attached or referenced beyond the notice, and the document length is short (1058 characters). This fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement and does not fit into more specific categories like Annual Report, Interim Report, or Board/Management Information (which would be for changes in board or management, not meeting notices).
2021-01-14 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice to stock exchanges about an upcoming Board Meeting to consider and approve unaudited financial results for the quarter ended December 31, 2020. It is an announcement of a meeting, not the financial results themselves. The document is short (1159 characters) and serves as an intimation or notice rather than containing financial data or analysis. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement related to compliance with SEBI listing obligations.
2021-01-13 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2021-01-08 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.